BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28567420)

  • 1. Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation.
    Fan L; Fu D; Zhang J; Huang H; Wang Q; Ye Y; Xie Q
    Biomed Res Int; 2017; 2017():5462087. PubMed ID: 28567420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.
    Fan L; Hong J; Huang H; Fu D; Wu S; Wang Q; Ye Y; Liu Y
    Med Sci Monit; 2017 May; 23():2636-2643. PubMed ID: 28557972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma.
    Kim H; Sohn HJ; Kim S; Lee JS; Kim WK; Suh C
    Bone Marrow Transplant; 2006 Jun; 37(11):1037-42. PubMed ID: 16708062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
    Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B; Svensson H; Goldschmidt H; Ljungman P; Apperley J; Mandelli F; Marcus R; Boogaerts M; Alegre A; Remes K; Cornelissen JJ; Bladé J; Lenhoff S; Iriondo A; Carlson K; Volin L; Littlewood T; Goldstone AH; San Miguel J; Schattenberg A; Gahrton G
    Bone Marrow Transplant; 2001 Mar; 27(5):511-5. PubMed ID: 11313685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.
    Lee HS; Min CK; Lee JJ; Kim K; Kim SJ; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC; Lee MH;
    Ann Hematol; 2016 May; 95(6):911-9. PubMed ID: 27052989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
    Shin HJ; Kim K; Lee JW; Song MK; Lee JJ; Lee HS; Lee WS; Kim SJ; Chung JS
    Eur J Haematol; 2014 Nov; 93(5):414-21. PubMed ID: 24813053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey.
    Ciftciler R; Goker H; Buyukasık Y; Aladag E; Saglam EA; Demiroglu H
    Transfus Apher Sci; 2019 Jun; 58(3):313-317. PubMed ID: 30928228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation.
    Song MK; Chung JS; Lee JJ; Min CK; Ahn JS; Lee SM; Shin DY; Bae SH; Hong J; Lee GW; Lee IS; Shin HJ
    Br J Haematol; 2014 Jun; 165(6):777-85. PubMed ID: 24628463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Blood Transfusion in Elderly Patients with Primary Diffuse Large B-Cell Lymphoma.
    Fan L; Fu D; Hong J; Huang H; He W; Zeng F; Lin Q; Xie Q
    Biomed Res Int; 2018; 2018():6742646. PubMed ID: 29750167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma.
    Lee SE; Kim JH; Jeon YW; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Min CK
    Ann Hematol; 2015 Mar; 94(3):445-52. PubMed ID: 25257340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma.
    Blix ES; Kildal AB; Bertelsen E; Waage A; Myklebust JH; Kolstad A; Husebekk A
    Biol Blood Marrow Transplant; 2015 May; 21(5):840-7. PubMed ID: 25689789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.
    Akkök CA; Liseth K; Nesthus I; Løkeland T; Tefre K; Bruserud O; Abrahamsen JF
    Transfusion; 2008 May; 48(5):877-83. PubMed ID: 18298599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
    Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
    Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival of older patients with multiple myeloma in the era of novel agents.
    Mey UJ; Leitner C; Driessen C; Cathomas R; Klingbiel D; Hitz F
    Hematol Oncol; 2016 Dec; 34(4):217-223. PubMed ID: 25898820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.